Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.57 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
| ▸ | GALR1 | P47211 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451413 | 0.93 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL5445443 | 0.91 | TRPV1 (0.54) | TRPV1GALR2GALR1 | |
| SCHEMBL5449369 | 0.86 | LMNA (0.44) | TRPV1HSD11B1 | |
| SCHEMBL5449092 | 0.83 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL5442067 | 0.83 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL3876611 | 0.81 | HSD11B1 (0.50) | TRPV1HSD11B1 | |
| SCHEMBL3877885 | 0.81 | HSD11B1 (0.52) | TRPV1GALR2GALR1HSD11B1 | |
| SCHEMBL3877516 | 0.81 | TRPV1 (0.48) | TRPV1GALR2GALR1HSD11B1 | |
| SCHEMBL5446888 | 0.80 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL3878763 | 0.80 | TRPV1 (0.49) | TRPV1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | claimed |
| EP-1651636-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007646-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | TRPV1 402/4885GALR2 34/4885GALR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.